MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 5, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven poster presentations at the 37th Annual Meeting of the
MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 16, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that it will provide a corporate
MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 16, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter
MONROVIA, Calif. , Feb. 5, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer, today announced that it will webcast presentations
MONROVIA, Calif. , April 29, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced it will webcast presentations by
Monrovia, Calif. – March 9, 2011 – Xencor, Inc. announced positive results from preclinical studies of XmAb®5871, a humanized monoclonal antibody that dually targets CD19 and CD32b (FcyRIIb) for the treatment of autoimmune diseases, demonstrating that XmAb5871 is a potent suppressor of B cell
MONROVIA, Calif. , May 11, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced today that XmAb®5871 has been granted
MONROVIA, Calif. , Sept. 24, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that its partner CSL Limited has
MONROVIA, Calif., October 1, 2013—Xencor, Inc. today announced that the first patient has been dosed in the Phase 2a part of its ongoing Phase 1b/2a clinical trial of XmAb®5871 in patients with active rheumatoid arthritis. XmAb5871 is the first in Xencor's class of therapeutic antibodies